Type(s) of chemotherapy-Protocols (combined treatment)-CHOP Posts on Medivizor
Navigation Menu

Type(s) of chemotherapy-Protocols (combined treatment)-CHOP Posts on Medivizor

Comparing outcomes after adding two doses of rituximab to R-CHOP chemotherapy for aggressive B-cell lymphoma

Posted by on Jan 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of six versus eight doses of rituximab (Rituxan) in R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for patients with aggressive B-cell lymphoma. This study concluded that adding two extra doses of rituximab to R-CHOP had similar outcomes in these...

Read More

Do ACE inhibitors help with anthracycline-induced cardiotoxicity in leukemia and lymphoma?

Posted by on Dec 6, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate if enalapril influences anthracycline-induced cardiotoxicity in children with leukemia and lymphoma. This study concluded that enalapril has a role in reducing anthracycline-induced cardiotoxicity in these patients. Some background Anthracyclines are a class of chemotherapy drugs that can be used for...

Read More

Evaluating radioimmunotherapy versus rituximab maintenance therapy in follicular lymphoma

Posted by on Oct 5, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the outcomes of radioimmunotherapy versus rituximab (Rituxan) maintenance therapy in patients with follicular lymphoma (FL). This study concluded that radioimmunotherapy shows similar survival outcomes compared to rituximab maintenance therapy in patients with FL. Some background In patients with FL, rituximab...

Read More

Long-term outcomes of radioimmunotherapy in patients with follicular lymphoma

Posted by on Oct 5, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term outcomes of radioimmunotherapy following first-line (primary) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced-stage follicular lymphoma (FL). This study concluded that this treatment approach is effective and well-tolerated in...

Read More

Evaluating rituximab maintenance therapy for mantle cell lymphoma

Posted by on Aug 11, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness of rituximab (Rituxan) maintenance therapy (treatment that is meant to help a primary treatment succeed) in patients with mantle cell lymphoma. The study concluded that this therapy improved survival outcomes in these patients after stem cell transplantation. Some background Chemoimmunotherapy is...

Read More

Predicting outcomes for patients with DLBCL using the albumin to globulin ratio

Posted by on Aug 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the significance of the albumin to globulin ratio in pretreated patients with diffuse large B-cell lymphoma. The study concluded that this ratio was useful for predicting treatment outcomes in these patients. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the most...

Read More

Comparing survival outcomes for elderly DLBCL patients receiving different first-line chemotherapies

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effects of different chemotherapies on the survival outcomes of elderly patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CHOP treatment is associated with very good survival in elderly patients with DLBCL. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...

Read More

What are the outcomes for B-cell lymphoma patients who receive salvage treatment for cancer that does not respond to R-CHOP chemotherapy?

Posted by on Apr 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the outcomes of different salvage treatments in patients with aggressive B-cell non-Hodgkin lymphoma with PET-positive disease (remaining cancer cells) after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. This study concluded that B-cell NHL patients with PET-positive...

Read More

Does PET/CT scanning during chemotherapy improve IPI-based outcome predictions for DLBCL patients?

Posted by on Feb 28, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated whether interim FDG PET/CT scanning during chemotherapy helps predict risk for new DLBCL (diffuse large B-cell lymphoma) patients. This study concluded that this scanning improves the risk classifications used to predict outcomes for DLBCL patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most...

Read More

How safe and effective is R-CHOP as a first-line treatment for patients with FL in the long-term?

Posted by on Jan 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of R-CHOP (rituximab combined with cyclophosphamide, doxorubicin, vincristine, prednisone) to CHOP-RIT (CHOP followed by iodine-133-tositumomab, Bexxar) as a first-line treatment for follicular lymphoma (FL) patients. This study concluded that immunochemotherapy should remain the standard...

Read More

Using obintuzumab plus CHOP or bendamustine to treat patients with follicular lymphoma

Posted by on Oct 14, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of obinutuzumab (Gazyva) plus CHOP chemotherapy vs obinutuzumab plus bendamustine (Treanda) in treating patients with follicular lymphoma. The study concluded that both obinutuzumab plus CHOP and obinutuzumab plus bendamustine are effective at treating patients with follicular...

Read More